Latest Conference Articles

Olanzapine, an antipsychotic medication that is often used off-label, has proved highly effective in controlling breakthrough chemotherapy-induced nausea and vomiting.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Dr. Maurie Markman, Cancer Treatment Centers of America, on Primary Care Physician Awareness of Long-Term Chemotherapy Side Effects

Many primary care providers and some oncologists are unaware of the long-term effects of four chemotherapy drugs used to treat two of the most common forms of cancer.

Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL

Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.

Dr. Shayma Kazmi, from Cancer Treatment Centers of America, on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting

Five nurses discuss the value of the Oncology Nursing Society (ONS) Annual Congress, which is the largest meeting held specifically for oncology nurses.

The Oncology Nursing Society (ONS) 37th Annual Congress video highlights, from OncLive TV.

The Oncology Nursing Society (ONS) 37th Annual Congress Picture Slideshow.

A recap of our coverage from the Oncology Nursing Society 37th Annual Congress, in New Orleans, where thousands of oncology nurses gathered and shared valuable clinical insights.

Mary Gullatte, the president of the Oncology Nursing Society, Discusses Nursing Shortages

Carol Bush, BS, RN, from the The University of Kansas Cancer Center, on the Midwest Cancer Alliance Telehealth Network

Universal tumor testing and a detailed personal and family history assessment are recommended for all patients with newly diagnosed colorectal cancer.

Erin McMenamin, MSN, from the Hospital of the University of Pennsylvania, on HPV-related Head & Neck Cancer Prognosis

The chemotherapy safety standards developed by ASCO and ONS were recently updated to reflect the fact that chemotherapy is delivered in a variety of settings.

Krista Rubin, MS, RN, FNP-BC, from Massachusetts General Hospital Cancer Center, on Managing Ipilimumab-related Dermatitis.

Standards for identifying appropriate populations for treatment with HER2-targeted therapies are evolving.

Michael Eckenfels, RN, OCN, from MD Anderson Cancer Center, on Changes to the Bortezomib Delivery Route.

Anna Vioral, RN, OCN, from West Penn Allegheny Health System, on Multidisciplinary Chemotherapy Safety Standards.

All oncology nurses-not just nurse researchers-will need to understand the fundamentals of clinical trials as patient access to the studies continues to expand.

Treatment of head and neck cancer often leaves patients with aftereffects that are bothersome at the very least and life-altering at their worst.

Anne Katz, from the University of Manitoba, Discusses Cancer and Sexuality

Nurses play vital roles in assuring that patients with metastatic castration-resistant prostate cancer (mCRPC) are optimally treated with sipuleucel-T.

A pilot study has demonstrated a lag in the integration of genetics and genomics into nursing practice, which is an increasingly required professional skill for oncology nurses.

Jayshree Shah, from John Theurer Cancer Center, on the Safety and Efficacy of Nilotinib for Patients With CML

Kim Kelly, from John Theurer Cancer Center, on the Updated MASCC/ISOO Clinical Practice Guidelines for Mucositis

With four full days of programming, dozens of exhibitors, satellite symposia, and thousands of members in attendance, trying to fit everything in at the ONS Annual Congress can prove quite challenging.

This year's ONS Annual Congress marks the first at which Mary Gullatte, PhD, RN, APRN, BC, AOCN, will serve as the organization's president.